Glycomimetics Stock Price, News & Analysis

GlycoMimetics, Inc. (Nasdaq: GLYC) announced the initiation of a Phase 1b/2 clinical trial for uproleselan, aimed at treating patients with treated secondary acute myeloid leukemia (ts-AML). The trial, led by Dr. Tapan Kadia at The University of Texas MD Anderson Cancer Center, focuses on the drug's safety, tolerability, and efficacy in a high-risk patient cohort. Uproleselan, a breakthrough therapy candidate, targets E-selectin to overcome treatment resistance in these patients. The study will enroll around 25 participants, assessing various efficacy endpoints.

GlycoMimetics, Inc. (Nasdaq: GLYC) has commenced a clinical study at UC Davis Comprehensive Cancer Center to evaluate uproleselan combined with venetoclax and azacitidine for older patients with treatment-naïve acute myeloid leukemia (AML). The trial aims to address unmet needs in AML treatments, particularly in patients exhibiting drug resistance. Early results from preclinical studies indicate that uproleselan may improve responses in patients resistant to current therapies. A recommended Phase 2 dose will be established, with preliminary results expected in 2022.

GlycoMimetics, Inc. (Nasdaq: GLYC) announces that CEO Rachel King will present a company overview at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, from 2:30 to 2:55 p.m. The company focuses on developing glycobiology-based therapies for acute myeloid leukemia (AML) and breast cancer. Its leading drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is being evaluated in a Phase 3 trial for relapsed/refractory AML. More details are available on their website.

GlycoMimetics, Inc. (Nasdaq: GLYC) has initiated an investigator-sponsored trial at Washington University School of Medicine to evaluate uproleselan's effectiveness in mitigating gastrointestinal toxicities associated with high-dose melphalan in patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. The Phase 2 study, led by Dr. Keith Stockerl-Goldstein, focuses on reducing diarrhea severity and assessing oral mucositis as secondary endpoints. Findings are expected by mid-2022, with uproleselan's prior Phase 2 results indicating potential benefits.

GlycoMimetics, Inc. (Nasdaq: GLYC) reported financial results for Q1 2021, highlighting cash and cash equivalents of $132.5 million. The company is optimistic about its lead program, uproleselan, which received Breakthrough Therapy Designation in China and has ongoing Phase 3 trials in the U.S. and NCI. Research and development expenses fell to $11.2 million, while general and administrative expenses decreased to $4.2 million. The promotion of Eric Feldman to Chief Medical Officer underscores leadership strength.

GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on May 3, 2021, at 8:30 a.m. ET to discuss its first quarter financial results. Domestic participants can dial (844) 413-7154, while international participants should call (216) 562-0466, using participant code 9891637. A replay of the webcast will be available on the company’s website for 30 days post-call. GlycoMimetics focuses on hematology-oncology, with drug candidates including uproleselan and rivipansel, designed for unmet medical needs in these fields.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced that an abstract for its preclinical study on GMI-1757 has been accepted for presentation at the AACR 2021 Annual Meeting. GMI-1757, a glycomimetic with dual antagonism to E-selectin and galectin-3, showed promising results in a pancreatic adenocarcinoma model, with 50% partial regressions and a ~99% reduction in median tumor volume. The compound improved anti-PD-L1 therapeutic activity, leading to favorable immune conditions. The presentation will be available online starting April 10, 2021.

GlycoMimetics, Inc. (Nasdaq: GLYC) reports promising results from a Phase 1b trial of GMI-1359 at Duke University Cancer Center. Initial findings reveal on-target effects, immune activation, and cell mobilization in two patients treated with the drug, a dual antagonist of E-selectin and CXCR4. No significant toxicities were noted, and the drug demonstrated an acceptable safety profile. Dorothy Sipkins, MD, will present these results at the AACR Annual Meeting, highlighting the potential of GMI-1359 to improve responses in metastatic breast cancer therapies.

GlycoMimetics (Nasdaq: GLYC) announced its abstract presentations at the AACR 2021 Annual Meeting, featuring an interim analysis of the Phase 1b study on GMI-1359, a dual antagonist targeting E-selectin and CXCR4 for treating cancers involving the bone. Also highlighted is GMI-1757, a novel compound with effects on fibrosis and therapeutic activity in pancreatic cancer. CEO Rachel King emphasized the significance of these studies in advancing treatment options for cancers with bone involvement. Both presentations are set for April 10, 2021.